Regulating fibrosis and muscle growth in the muscular dystrophies
Regulating fibrosis and muscle growth in the muscular dystrophies
批准号:
8868179
负责人:
Elizabeth M McNally
金额:
$122.9万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2017-06-30
关键词:
AdultAffectBindingBinding ProteinsCellsChildCicatrixCleaved cellCollaborationsCollagenComplexDataDepositionDiseaseDoctor of MedicineDoctor of PhilosophyDuchenne muscular dystrophyDyesDystrophinEvans blue stainFamily memberFibrosisGenesGeneticGenetic screening methodGoalsGrowthHereditary DiseaseInfiltrationInstitutionKnockout MiceLaboratoriesLeadLengthLimb-Girdle Muscular DystrophiesMeasuresMediatingMembraneModelingMolecular GeneticsMuscleMuscle WeaknessMuscle functionMuscular DystrophiesNatural regenerationOutcomeOutcome MeasurePathogenesisPathologyPathway interactionsPeptide HydrolasesPlayPrincipal InvestigatorProcessResearchResearch PersonnelRoleSarcoglycansSignal PathwaySignal TransductionTGFB1 geneTechniquesTestingTherapeuticbasecytokinegenetic manipulationimprovedin vivomouse modelmuscle degenerationmuscle formmuscle regenerationmyostatinoverexpressionprotein complexpublic health relevancereceptorresearch studyscaffolduptake
中文摘要
描述(由申请人提供):肌肉萎缩症是一种无法治愈的遗传性疾病。肌营养不良最严重的形式之一是杜氏肌营养不良(DMD)。DMD和肢带肌营养不良症的一个子集有共同的肌营养不良蛋白复合物的破坏。破坏肌营养不良蛋白复合体会导致脆弱的肌膜,肌纤维的损失和肌肉纤维化或瘢痕的替代。多种证据表明纤维化是肌营养不良病理的驱动因素。我们假设纤维化提供了一个支架,促进不利的细胞因子谱,进一步损害肌肉。我们进一步假设,不利的细胞因子谱的主要成分是TGFp和相关的TGFp家族成员肌生成抑制素。TGFp和肌肉生长抑制素共同导致纤维化增加,肌肉质量和再生减少,并加剧了膜的脆弱性。因此,我们建议确定TGFp和肌肉生长抑制素通常被基质隔离的方式,使其无法参与受体接合和信号传导,并确定如何促进肌肉萎缩症中TGFp和肌肉生长抑制素的失活(项目1)。我们还将展示肌肉生长抑制素和相关分子释放和加工所需的蛋白水解裂解步骤,以及可溶性受体在治疗肌肉萎缩症中的有效程度(项目2)。我们还将依次评估由TGFp和肌生长抑制素触发的不同细胞内信号通路,并测试抑制这些通路是否能改善肌营养不良患者的肌肉功能和病理(项目3)。三位已成立的研究者(McNally, Lee和Molkentin)将领导这些项目,组成一个独特的团队,他们的综合专业知识将定义TGFp/肌生长抑制素途径,以治疗肌肉萎缩症。三个核心将支持这些项目;核心A将整合我们三个机构的努力,以确保材料的无缝协作和转移。Core B将提供基因操作和治疗后肌肉萎缩症的组织病理学评估,Core C将进行体内功能分析并为Core B提供支持。
英文摘要
DESCRIPTION (provided by applicant): Muscular dystrophy is a genetic disease for which there is no cure. One of the most severe forms of muscular dystrophy is Duchenne Muscular Dystrophy (DMD). DMD and a subset of the limb girdle muscular dystrophies have in common disruption of the dystrophin protein complex. Disrupting the dystrophin complex lead to a fragile muscle membrane, loss of myofibers and replacement of the muscle with fibrosis or scarring. Multiple lines of evidence point to fibrosis is as a driver of muscular dystrophy pathology. We hypothesize that fibrosis provides a scaffold that promotes an unfavorable cytokine profile that further damages muscle. We further hypothesize that the primary components of the unfavorable cytokine profile are TGFp and the related TGFp family member myostatin. Together, TGFp and myostatin, lead to increased fibrosis, reduced muscle mass and regeneration, and aggravated membrane fragility. Therefore, we propose to determine the means by which TGFp and myostatin are normally sequestered by the matrix and held unavailable for receptor engagement and signaling and to determine how to promote inactivation of TGFp and myostatin in muscular dystrophy (Project 1). We will also demonstrate necessary proteolytic cleavage steps for release and processing of myostatin, and related molecules, and the degree to which soluble receptors can be effective in treating muscular dystrophy (Project 2). We will also sequentially assess the distinct intracellular signaling pathways that are triggered by TGFp and myostatin and test whether inhibiting these pathways improves muscle function and pathology in muscular dystrophy (Project 3). Three established investigators (McNally, Lee, and Molkentin) will lead these projects forming a distinctive team where their combined expertise will define the TGFp/myostatin pathway for therapeutic intent in muscular dystrophy. Three Cores will support the Projects; Core A will integrate the efforts at our three institutions to assure seamless collaboration and transfer of materials. Core B will provide histopathological assessment of muscular dystrophy after genetic manipulation and treatments, and Core C will perform functional analysis in vivo and provide support to Core B.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Genetic overexpression of Serpina3n attenuates muscular dystrophy in mice.
Serpina3n 的基因过度表达可减轻小鼠的肌营养不良症。
DOI:
10.1093/hmg/ddw005
发表时间:
2016
期刊:
Human molecular genetics
影响因子:
3.5
作者:
[Tjondrokoesoemo,Andoria, Schips,Tobias, Kanisicak,Onur, Sargent,MichelleA, Molkentin,JefferyD]
通讯作者:
Molkentin,JefferyD
DOI:
10.1038/cdd.2015.65
发表时间:
2015-09
期刊:
Cell death and differentiation
影响因子:
12.4
作者:
[Burr AR, Molkentin JD]
通讯作者:
Molkentin JD
DOI:
10.1371/journal.pone.0082053
发表时间:
2013
期刊:
PloS one
影响因子:
3.7
作者:
[Davis J, Kwong JQ, Kitsis RN, Molkentin JD]
通讯作者:
Molkentin JD
Bridging Basic and Translational Science in Cardiovascular Disease
-
批准号:10540546
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2022
-
负责人:Elizabeth M McNally
-
依托单位:
Cardiomyopathy Genomes Project
-
批准号:10406096
-
项目类别:
-
资助金额:$3.77万
-
财政年份:2021
-
负责人:Elizabeth M McNally
-
依托单位:
New Frontiers in Cardiovascular Research and Therapy
-
批准号:10318721
-
项目类别:
-
资助金额:$2.4万
-
财政年份:2021
-
负责人:Elizabeth M McNally
-
依托单位:
Failed Regeneration in the Muscular Dystrophies: Inflammation, Fibrosis and Fat - Administrative Supplement
-
批准号:10212504
-
项目类别:
-
资助金额:$40.39万
-
财政年份:2020
-
负责人:Elizabeth M McNally
-
依托单位:
New Directions in Biology and Disease of Skeletal Muscle
-
批准号:10400988
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2020
-
负责人:Elizabeth M McNally
-
依托单位:
Northwestern University Molecular and Translational Cardiovascular Training Program
-
批准号:10197196
-
项目类别:
-
资助金额:$33.5万
-
财政年份:2017
-
负责人:Elizabeth M McNally
-
依托单位:
Cardiomyopathy Genomes Project
-
批准号:10161812
-
项目类别:
-
资助金额:$59.82万
-
财政年份:2015
-
负责人:Elizabeth M McNally
-
依托单位:
Cardiomyopathy Genomes Project
-
批准号:9923714
-
项目类别:
-
资助金额:$65.03万
-
财政年份:2015
-
负责人:Elizabeth M McNally
-
依托单位:
Cardiomyopathy Genomes Project
-
批准号:9061822
-
项目类别:
-
资助金额:$54.36万
-
财政年份:2015
-
负责人:Elizabeth M McNally
-
依托单位:
Cardiomyopathy Genomes Project
-
批准号:10615197
-
项目类别:
-
资助金额:$57.53万
-
财政年份:2015
-
负责人:Elizabeth M McNally
-
依托单位:
Myoferlin in muscle membrane fusion and repair
-
批准号:8990655
-
项目类别:
-
资助金额:$31.97万
-
财政年份:2015
-
负责人:Elizabeth M McNally
-
依托单位:
Cardiomyopathy Genomes Project
-
批准号:10403645
-
项目类别:
-
资助金额:$57.53万
-
财政年份:2015
-
负责人:Elizabeth M McNally
-
依托单位:
Cardiomyopathy Genomes Project
-
批准号:9929858
-
项目类别:
-
资助金额:$5.21万
-
财政年份:2015
-
负责人:Elizabeth M McNally
-
依托单位:
Sarcoglycan in Myopathy and Muscle Membrane Stability
-
批准号:8915736
-
项目类别:
-
资助金额:$37.77万
-
财政年份:2014
-
负责人:Elizabeth M McNally
-
依托单位:
New Directions in Biology and Disease of Skeletal Muscle
-
批准号:8720398
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2014
-
负责人:Elizabeth M McNally
-
依托单位:
Sarcoglycan in Myopathy and Muscle Membrane Stability
-
批准号:8786782
-
项目类别:
-
资助金额:$4.52万
-
财政年份:2014
-
负责人:Elizabeth M McNally
-
依托单位:
Sarcoglycan in Myopathy and Muscle Membrane Stability
-
批准号:8987217
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2014
-
负责人:Elizabeth M McNally
-
依托单位:
New Directions in Biology and Disease of Skeletal Muscle
-
批准号:8400254
-
项目类别:
-
资助金额:$3.25万
-
财政年份:2012
-
负责人:Elizabeth M McNally
-
依托单位:
Regulating fibrosis and muscle growth in the muscular dystrophies
-
批准号:8294625
-
项目类别:
-
资助金额:$126.29万
-
财政年份:2011
-
负责人:Elizabeth M McNally
-
依托单位:
Regulating fibrosis and muscle growth in the muscular dystrophies
-
批准号:8151770
-
项目类别:
-
资助金额:$125.65万
-
财政年份:2011
-
负责人:Elizabeth M McNally
-
依托单位:
海外基金